KardiaMobile® Card
November 1, 2022
Austria
December 1, 2022Viz.ai
Overview
Viz.ai uses artificial intelligence (AI) to coordinate stroke care, reducing systematic gaps between patients and treatments that save lives. In their network, their AI products detect and alert stroke teams within minutes to suspected large vessel occlusion strokes in CT perfusion studies. Using a HIPAA-compliant mobile app, stroke teams can consult in real-time, driving immediate treatment decisions that save brains and lives.
AI Aspects
AI-Powered LVO Detection: Viz LVO uses AI to automatically recognize suspected large vessel occlusion strokes on CT angiogram imaging and to alert the on-call stroke team within minutes.
Automated CTP Analysis: Viz CTP uses advanced imaging technology to automatically analyze CT perfusion images of the brain, create parametric color maps, and measure CT perfusion parameters.
HIPAA-Compliant Messaging: Viz HUB is a stable, HIPAA-compliant text messaging and calling platform that empowers clinical teams between hospitals in a hub and spoke network to effectively achieve patient care and treatment choices.
Mobile DICOM Image Viewer. Viz VIEW is a mobile, non-diagnostic image viewer that allows any Android or Apple phone to dynamically view Digital Imaging and Communications in Medicine (DICOM) images.
Viz PAGER. Provides early patient information to the clinical team and the immediate opportunity to chat and synchronize care before the patient reaches the hospital.
Viz LINK. To promote cryptogenic follow-up, Viz connects neurology and cardiology. A consultation/referral may be done directly inside the app for ongoing atrial fibrillation monitoring.
Viz LVO. The first FDA-cleared technology was developed to automatically identify and triage suspected LVOs using AI to identify suspected LVOs on CTA imaging. Viz LVO uses AI and specifically warns on-call stroke specialists about potentially treatable patients through a multi-hospital network.(1)
Viz.ai’s technology overview. Viz uses proprietary AI and deep learning technologies to automatically detect and alert clinicians to acute pathology and is paired with a PACS quality mobile image viewer and HIPAA-compliant communication platform to facilitate synchronized coordination of care to stroke patients.
Ischemic stroke platform: include automated and AI-driven large vessel occlusion, advanced CTP perfusion, NCCT, CTA, and MRI viewing, and simplified ASPECTS scoring. Viz can also integrate with EMS for pre-hospital care coordination with Viz PAGER and post-acute care referrals for cryptogenic stroke patients directly to cardiology with Viz LINK.
Viz has demonstrated significant time saving by alerting the treating specialist as early as possible in the workflow and enabling sooner coordination of care.
- Viz LVO: identify suspected large vessel occlusion strokes on CT angiogram imaging in the network and alert the on-call stroke team within minutes
- Viz CTP: analyze CT perfusion images of the brain, produce parametric color maps, and calculate CT perfusion parameters.
- Viz HUB: is a secure, HIPPA-compliant text messaging and calling platform that empowers clinical teams to conveniently coordinate patient care and treatment decision between the hospital and spoke network.
- Viz Recruit: alerts the research team and PI about potentially eligible trial patients across the entire center and spoke network and enables easy communication between clinical teams, research teams, and core lab to facilitate enrollment.
Viz has demonstrated significant time saving by alerting the treating specialist as early as possible in the workflow and enabling sooner coordination of care.
- Viz LVO: identify suspected large vessel occlusion strokes on CT angiogram imaging in the network and alert the on-call stroke team within minutes
- Viz CTP: analyze CT perfusion images of the brain, produce parametric color maps, and calculate CT perfusion parameters.
- Viz HUB: is a secure, HIPPA-compliant text messaging and calling platform that empowers clinical teams to conveniently coordinate patient care and treatment decision between the hospital and spoke network.
- Viz Recruit: alerts the research team and PI about potentially eligible trial patients across the entire center and spoke network and enables easy communication between clinical teams, research teams, and core lab to facilitate enrollment.
CMS Grants Viz LVO New Technology Add-On Payment (NTAP)
NTAP recognizes that current payment rates can be a barrier to adopting new technology. NTAP is an additional add-on payment system for hospital stays that uses new technology. The CMS determined that this system provides substantial clinical improvement and can be used where the current MS-DRG payment is inadequate. Viz LVO is the first AI medical software to receive NTAP. Viz demonstrated to CMS a significant reduction in time to treatment and improved clinical outcomes in patients with stroke.(2)
Viz.ai’s financial aspects.
Viz has raised $50 million in a Series B round of funding led by Greenoaks, with participation from Alphabet’s VC arm GV and Kleiner Perkins. Viz.ai‘s inaugural product received FDA clearance in 2018. Since 2019, it has been used in more than 300 hospitals across the U.S. Viz.ai has raised $30 million in funding, including its $21 million series A round in 2017 that saw GV and Kleiner Perkins, once again, join forces. With another $50 million in the bank, the company is well-financed to expand its software to more locations.(3)
AI Helps Stroke Triage System
Viz LVO is an artificial intelligence software application that can examine brain computed tomography angiography (CTA) images in cases of stroke suspicion. 2544 patient scans were analyzed, and a total of 163 large vessel occlusions (LVOs) were identified. Results showed that both sensitivity and specificity were approximately 94%, and the average time of the software report was 5 minutes and 45 seconds. The timeliness and high sensitivity and specificity may have tremendous implications in helping clinicians order the right treatment in a short time.(4)
Viz LVO is an artificial intelligence software application that can examine brain computed tomography angiography (CTA) images in cases of stroke suspicion. 2544 patient scans were analyzed, and a total of 163 large vessel occlusions (LVOs) were identified. Results showed that both sensitivity and specificity were approximately 94%, and the average time of the software report was 5 minutes and 45 seconds. The timeliness and high sensitivity and specificity may have tremendous implications in helping clinicians order the right treatment in a short time.(4)
AI Detection of Cerebrovascular Large Vessel Occlusion: Accuracy and Performance of the Viz.ai LVO Algorithm
Accurate and timely diagnosis of Large Vessel Occlusion (LVO) for Acute Ischemic Stroke (AIS) by CTA is essential for efficient endovascular reperfusion therapy. The Viz LVO is a system developed to evaluate head and neck CTAs using AI to diagnose anterior circulation LVOs from the ICA-T to the Sylvian MCA M1 segments. In this study, researchers assessed the diagnostic accuracy and notification time of Viz LVO compared with our institutional standard of care. The Viz AI algorithm evaluated 650 CTAs. The processing time and automatic detection were recorded. The CTAs were compared against the radiology report, the radiologist to stroke care team time-to-notification, and with an independent review. Viz.ai demonstrated a sensitivity of 82%, specificity of 94%, positive predictive value of 77%, and negative predictive value of 95%. The mean processing time for Viz.ai was 5 minutes, with a maximum of 8 minutes for all studies.(5)
Accurate and timely diagnosis of Large Vessel Occlusion (LVO) for Acute Ischemic Stroke (AIS) by CTA is essential for efficient endovascular reperfusion therapy. The Viz LVO is a system developed to evaluate head and neck CTAs using AI to diagnose anterior circulation LVOs from the ICA-T to the Sylvian MCA M1 segments. In this study, researchers assessed the diagnostic accuracy and notification time of Viz LVO compared with our institutional standard of care. The Viz AI algorithm evaluated 650 CTAs. The processing time and automatic detection were recorded. The CTAs were compared against the radiology report, the radiologist to stroke care team time-to-notification, and with an independent review. Viz.ai demonstrated a sensitivity of 82%, specificity of 94%, positive predictive value of 77%, and negative predictive value of 95%. The mean processing time for Viz.ai was 5 minutes, with a maximum of 8 minutes for all studies.(5)
AI Identifies Large Vessel Occlusion
Viz.ai utilizes AI-powered large vessel occlusion (LVO) detection technology that can identify LVO with CTA imaging reduction.
This software provides imaging and information that allows the physician at the Comprehensive Stroke Center (CSC) to confirm LVO and thus transfer the patients to CSC. A total of 43 patients were analyzed, of which 28 were from the pre-AI software, and 15 were from the post-AI software. AI software proved that the median CTA time at the primary stroke center (PSC) to door-in at CSC was reduced by 22.5 min. The endovascular therapy decision proved quick in LVO patients who presented to a PSC needing CTA and Endovascular therapy. AI software could also benefit from reducing costs and improving patient outcomes.(6)
Viz.ai utilizes AI-powered large vessel occlusion (LVO) detection technology that can identify LVO with CTA imaging reduction.
This software provides imaging and information that allows the physician at the Comprehensive Stroke Center (CSC) to confirm LVO and thus transfer the patients to CSC. A total of 43 patients were analyzed, of which 28 were from the pre-AI software, and 15 were from the post-AI software. AI software proved that the median CTA time at the primary stroke center (PSC) to door-in at CSC was reduced by 22.5 min. The endovascular therapy decision proved quick in LVO patients who presented to a PSC needing CTA and Endovascular therapy. AI software could also benefit from reducing costs and improving patient outcomes.(6)
Comparison of Automated CT Perfusion Software for Prediction of Final Infarct Volume
Viz.ai‘s perfusion software allows for automated and faster processing using standardized approaches. This study compared the perfusion parameters and final infarct volume RPID (FIV) predictability of two commercially available CT Perfusion packages (RPID and Viz.ai). A retrospective analysis of a mechanical thrombectomy database of mechanical thrombectomy. A total of 164 patients were included. Patients with complete post-treatment reperfusion and absence of parenchymal hematoma that could confound FIV calculation were used to derive the correlation between baseline core and FIV. The RAPID and Viz.ai systems have a strong correlation in terms of the overall baseline parameters and reperfusion treatment eligibility.(7)